GlassScriptPhysician profile
Eduardo J Hernandez
NPI 1881900454
$5,249.64
in general payments reported to CMS, 2019-2025
24 companies · $755 in 2025
The $755 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $456 · 2021: $520 · 2022: $1,762 · 2023: $454 · 2024: $1,178 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261 · Travel and Lodging: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.52 |
| Travel and Lodging | $1,126.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,571.87 | 2021-2023 | Urolift |
| Coloplast Corp | $725.15 | 2021-2025 | |
| Boston Scientific Corporation | $650.05 | 2019-2022 | |
| Intuitive Surgical, INC. | $597.05 | 2023-2025 | Da Vinci Surgical System |
| Procept Biorobotics Corporation | $284.32 | 2020-2024 | Aquabeam System |
| Urogen Pharma, INC. | $163.67 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $161.37 | 2024 | Keytruda |
| Neotract INC. | $159.48 | 2020 | |
| Olympus America INC. | $139.99 | 2025 | Itind System |
| Karl Storz Endoscopy-America | $130.14 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $116.79 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $98.58 | 2021-2023 | Myrbetriq |
| Axonics, INC. | $93.71 | 2023-2024 | Axonics, Bulkamid |
| Myriad Genetic Laboratories, INC. | $59.23 | 2023 | Precisetumor, Myrisk, Prolaris |
| Endo USA, INC. | $49.38 | 2024 | Xiaflex |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $44.16 | 2020-2021 | |
| Ambu INC. | $37.47 | 2021 | |
| Abbvie INC. | $32.68 | 2023-2025 | |
| Photocure INC | $29.76 | 2025 | Cysview |
| Bayer Healthcare Pharmaceuticals INC. | $28.92 | 2023 | |
| Acerus Pharmaceuticals Corporation | $24.37 | 2022 | |
| Pfizer INC. | $19.72 | 2023 | |
| Laborie Medical Technologies Corp. | $16.06 | 2024 | |
| Verity Pharmaceuticals INC. | $15.72 | 2023 | Trelstar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.